4. 5 for yderligere oplysninger om potentielle interaktioner med HMG- CoA reduktasehæmmere).
Lipid disorders are to be managed as clinically appropriate (see also section 4.5 for additional information on potential interactions with HMG-CoA reductase inhibitors).